We are an early stage research company developing a platfrom for the detection and treatment of diseased cells using the detection of phophatidylserine (PS) on the cell surface to detect and target these cells. Based on a naturally occurring PS targeting motif (the Gla domain) this platform was acquired in 2018 from Bayer HealthCare and validated in collaboration with Stanford University School of Medicine. We are seeking to close out our seed funding and to identify a clinical candidate in 12-18 months.
Company HQ State:
Company HQ Country:
Main Therapeutic Focus:
Lead Product in Development:
Tumor targeted payloads of various classes
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):